Informations générales (source: ClinicalTrials.gov)
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies
Interventional
Phase 1
BeOne Medicines (Voir sur ClinicalTrials)
juin 2026
septembre 2028
01 octobre 2026
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in
combination with other agents in patients with myeloid malignancies.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | St�phane DE BOTTON | 29/10/2026 14:25:03 | Contacter | ||
Critères
Tous
- Patients must be ≥ 18 years of age (or the legal age of consent in the jurisdiction
in which the study is taking place), inclusive, at the time of signing the Informed
consent form (ICF).
- Patients must have a confirmed diagnosis of myeloid malignancies based on 2016 World
Health Organization criteria, and meet the following categories:
- Relapsed/refractory; myeloid malignancies after ≥1 prior systemic therapy, per
ELN; 2022 criteria; patients with actionable genetic alteration must have
previously received targeted therapies unless contraindicated,
unavailable/inaccessible, or declined by patient.
- Patients must have a stable Eastern Cooperative Oncology Group (ECOG) Performance
Status of 0-2.
Exclusion Criteria:
- Prior exposure to KAT6A/B inhibitors/degraders.
- A diagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia.
- Known central nervous system involvement by leukemia
- Use of antileukemic therapies without sufficient washout period
Note: Other protocol defined Inclusion/Exclusion criteria may apply.